Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$2.33
C$2.28
C$1.02
C$2.59
C$5.95M-1.2383473,893 shs2,172 shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$282.39
+14.1%
$273.25
$211.43
$343.12
$7.56B1.06317,154 shs1.26 million shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$2.00
C$2.11
C$1.51
C$5.00
C$25.38M2.651886,402 shs2,535 shs
ERGO
Entia Biosciences
$0.00
$0.01
$0.00
$0.04
N/A26.97465 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
0.00%-0.85%-1.69%+3.10%-1.27%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.00%-2.63%-17.09%-3.59%-0.32%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00%-2.44%-9.09%+0.50%0.00%
ERGO
Entia Biosciences
0.00%0.00%+500.00%+100.00%+500.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
C$2.33
C$2.28
C$1.02
C$2.59
C$5.95M-1.2383473,893 shs2,172 shs
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$282.39
+14.1%
$273.25
$211.43
$343.12
$7.56B1.06317,154 shs1.26 million shs
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$2.00
C$2.11
C$1.51
C$5.00
C$25.38M2.651886,402 shs2,535 shs
ERGO
Entia Biosciences
$0.00
$0.01
$0.00
$0.04
N/A26.97465 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
0.00%-0.85%-1.69%+3.10%-1.27%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.00%-2.63%-17.09%-3.59%-0.32%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00%-2.44%-9.09%+0.50%0.00%
ERGO
Entia Biosciences
0.00%0.00%+500.00%+100.00%+500.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
2.00
HoldN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
2.00
Hold$303.337.41% Upside
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.00
N/AN/AN/A
ERGO
Entia Biosciences
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest BU, APS, ERGO, and BIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Initiated CoverageOutperform$320.00
5/14/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
UpgradeModerate Buy
5/6/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
DowngradeSell (D+)Sell (D)
5/1/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
Lower Price TargetEqual Weight$320.00 ➝ $290.00
4/7/2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
DowngradeBuyNeutral$375.00 ➝ $300.00
(Data available from 5/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/AN/AC$1.46 per share1.60C($13.59) per shareN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$2.58B2.93$11.43 per share24.70$276.16 per share1.02
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
C$1.48M17.14C$0.05 per share39.00C($0.20) per share-10.21
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-C$154.69M-C$10.41N/AN/AN/AN/A115.24%-136.29%N/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$759.90M$6.0746.5230.36N/A6.52%3.56%2.49%7/30/2026 (Estimated)
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-C$12.74M-C$1.07N/AN/AN/A-870.87%-630.53%-39.22%N/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/AN/AN/AN/AN/A

Latest BU, APS, ERGO, and BIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2026Q1 2026
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
$1.97$1.89-$0.08-$19.55$589.91 million$592.10 million
3/31/2026Q4 2025
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A-C$4.07N/A-C$4.07N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
N/A0.39%N/AN/AN/A
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
N/AN/AN/AN/AN/A
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
N/A4.45%N/AN/AN/A
ERGO
Entia Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
-98.74
0.55
5.41
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
0.12
3.21
2.37
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
-1,514.36
0.22
1.71
ERGO
Entia Biosciences
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
0.02%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
65.24%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
0.05%
ERGO
Entia Biosciences
N/A

Insider Ownership

CompanyInsider Ownership
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
17.11%
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
30.34%
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
28.06%
ERGO
Entia Biosciences
28.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APS
Aptose Biosciences
312.55 millionN/ANot Optionable
Bio-Rad Laboratories, Inc. stock logo
BIO
Bio-Rad Laboratories
7,45026.76 million18.64 millionOptionable
Burcon NutraScience Co. stock logo
BU
Burcon NutraScience
2012.69 millionN/ANot Optionable
ERGO
Entia Biosciences
6N/AN/ANot Optionable

Recent News About These Companies

Careology partners with Entia to offer at home blood monitoring
The Best Ergonomic Keyboards for 2024
Hdfc Ergo
Top HDFC ERGO Health Insurance Plans
Cooler Master Hybrid 1 Ergo Gaming Chair Review
Entia Biosciences, Inc. (ERGO)
Entia Biosciences Inc (ERGO)
Entia Biosciences Dividend Per Share (TTM)
Entia Biosciences EPS Diluted (5 Year Growth)
Entia Biosciences Year to Date Total Returns (Daily)
BGF invests $12m in virtual oncology business Entia

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences TSE:APS

C$2.33 0.00 (0.00%)
As of 05/15/2026 03:58 PM Eastern

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Bio-Rad Laboratories stock logo

Bio-Rad Laboratories NYSE:BIO

$282.39 +34.86 (+14.08%)
Closing price 03:59 PM Eastern
Extended Trading
$290.00 +7.61 (+2.69%)
As of 06:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Burcon NutraScience stock logo

Burcon NutraScience TSE:BU

C$2.00 0.00 (0.00%)
As of 05/15/2026 01:23 PM Eastern

Burcon is a global technology leader in the development of plant-based proteins. With over 285 issued patents and more than 250 additional patent applications, that have been developed over a span of more than twenty years, Burcon has grown an extensive portfolio of composition, application, and process patents covering novel plant-based proteins derived from pea, canola, soy, hemp, sunflower seed and more. In 2019, Merit Functional Foods Corporation was established in a joint venture by Burcon and three veteran food industry executives. Merit Foods is building a state-of-the-art protein production facility in Manitoba, Canada, where it will produce, under license, Burcon's novel pea and canola protein ingredients.

Entia Biosciences OTCMKTS:ERGO

$0.0006 0.00 (0.00%)
As of 05/15/2026

Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.